92.73 (-%)
As of Nov 21, 2024
Source:
Nuvalent, Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our team’s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for “clinically proven” kinase targets.
Country | United States |
Headquarters | cambridge, massachusetts |
Phone Number | 508-446-2272 |
Industry | |
CEO | James R. Porter |
Website | http://www.nuvalent.com |